• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

Comparative efficacy and tolerability of evolocumab and ezetimibe in patients with statin intolerance

bySusy LamandMichael Milligan
April 5, 2016
in Cardiology, Chronic Disease, Endocrinology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Among patients with muscle-related statin intolerance, evolocumab reduced LDL-C levels significantly more than ezetimibe.

2. Evolocumab and ezetimibe had similar rates of muscle-related adverse events when compared to statins.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Statin therapy has been shown to be effective in reducing cholesterol levels in patients with hypercholesterolemia. However, it has been estimated that between 5% and 29% of patients on a statin will experience muscle-related side effects. Other, non-statin drugs, like ezetimibe are recommended for use in these patients, although their efficacy has been limited. Newer, non-statin drugs, including the PCSK9 inhibitor, evolocumab, may be more useful in lowering cholesterol in statin-intolerant patients. Thus, this double-blinded randomized controlled study compared the effectiveness and tolerability of ezetimibe and evolocumab in patients who experienced statin-related muscle side effects. The results showed that evolocumab reduced LDL-C levels significantly more than ezetimibe. Other lipid panel measurements were also significantly decreased in the evolocumab cohort, including non-HDL-C, ApoB, and total cholesterol.

This trial represents the most comprehensive study analysis of cholesterol levels in statin-intolerant patients, and suggests that PCSK9 inhibitors may be a useful alternative to statin medication in patients with muscle-related adverse events. However, this study was limited by its relatively small cohort, short follow-up, and limited number of adverse events, and more studies are needed to determine the full clinical utility of evolocumab.

Click to read the study in JAMA

Relevant Reading: Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management

RELATED REPORTS

Moderate-intensity statin plus ezetimibe is non-inferior to high-intensity statin monotherapy

Combination-drug therapy and earlier detection recommended to improve outcomes in heterozygous familial hypercholesterolemia

#VisualAbstract: Improved sleep quality reduced cardio-metabolic risk factors

In-Depth [randomized controlled trial]: This study aimed to quantify the effects of two non-statin medications, ezetimibe and evolocumab, in patients who experienced muscle-related adverse events to traditional statin therapy. The primary outcome measure was the change in LDL-C levels from baseline after 24 weeks of therapy. In the first phase of this study, 492 patients were given both a statin challenge and placebo over intervening weeks. A total of 209 (42.6%) patients experienced muscle symptoms while on a statin and not the placebo, and were eligible for the second phase of the study. During this second phase, 199 of the above qualified patients, and 19 others who had a history of elevated CK on statin therapy were randomized in a 2:1 ratio to receive evolocumab 420 mg monthly IV or ezetimibe 10 mg daily by mouth. LDL-C levels for the mean of weeks 22 and 24 were 183 mg/dL (95%CI 167.4 to 198.6 mg/dL; least-squares mean percent change from baseline -16.7%, 95%CI -20.5% to -12.9%) for ezetimibe and 103.6 mg/dL (95%CI 92.5 to 114.8 mg/dL; mean percent change -54.5%, 95%CI -57.2% to -51.8%) for evolocumab. The mean difference in LDL-C when comparing evolocumab to ezetimibe was -37.8% (95%CI -42.3% to -33.3%, p <  0.001). Muscle-related adverse events occurred in 28.8% of ezetimibe-treated patients and 20.7% of evolocumab-treated patients.

 

Image: PD

©2016 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: cholesterolezetimibe (Zetia)pcsk9
Previous Post

Clinician factors associated with increased PSA screening amongst veterans with limited life expectancy

Next Post

2 Minute Medicine Rewind April 4, 2016

RelatedReports

2 Minute Medicine Rewind October 12 – 19, 2014
Cardiology

Moderate-intensity statin plus ezetimibe is non-inferior to high-intensity statin monotherapy

August 10, 2022
2 Minute Medicine Rewind October 12 – 19, 2014
Cardiology

Combination-drug therapy and earlier detection recommended to improve outcomes in heterozygous familial hypercholesterolemia

November 16, 2021
#VisualAbstract: Improved sleep quality reduced cardio-metabolic risk factors
StudyGraphics

#VisualAbstract: Improved sleep quality reduced cardio-metabolic risk factors

July 15, 2021
Quick Take: Assessment of application-driven postoperative care in the pediatric tonsillectomy population: a survey-based pilot study
Weekly Rewinds

2 Minute Medicine Rewind July 27, 2020

July 28, 2020
Next Post
UTI associated with increased risk of preeclampsia

2 Minute Medicine Rewind April 4, 2016

Autologous hematopoietic stem cell transplantation associated with long-term remission in myasthenia gravis

Autologous hematopoietic stem cell transplantation associated with long-term remission in myasthenia gravis

High incidence of foreskin morbidity in uncircumcised males

High incidence of foreskin morbidity in uncircumcised males

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Subthreshold micropulse laser is equivalent to standard laser for treating diabetic macular edema
  • Gadolinium-containing contrast associated with nephrogenic fibrosing dermopathy and systemic fibrosis [Classics Series]
  • Study supports continued use of amoxicillin as first-line therapy for pediatric ear infections
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.